HSBC earlier today downgraded UnitedHealth (UNH) to Hold from Buy with a price target of $595, down from $610, post the Q3 report. The firm says they key debate on UnitedHealth is if the company can get back to 13%-16% adjusted earnings growth aspirations set by management or if some of the current headwinds being faced by the company will persist leading to a lower growth rate for the years to come. The “disappointing” 2025 guidance and the outlook cut for 2024 are a “rare event in UNH’s recent history,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- UnitedHealth price target lowered to $625 from $640 at Truist
- UnitedHealth price target lowered to $595 from $615 at RBC Capital
- UnitedHealth price target raised to $644 from $591 at Cantor Fitzgerald
- UnitedHealth price target lowered to $610 from $615 at Morgan Stanley
- UnitedHealth price target lowered to $650 from $675 at KeyBanc